Theravance Biopharma, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Theravance Biopharma, Inc. (TBPH) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$27.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2024-03-01
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-12-31 was -$854.00K, a 101.56% decline year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-09-30 was -$2.49M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-06-30 was -$12.44M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-03-31 was -$11.22M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2023 was -$27.00M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2022 was -$2.42M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2021 was -$235.78M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2020 was -$262.75M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$3.34M derived: sum of 2 quarters · filed 2024-03-01 | -$15.78M derived: sum of 3 quarters · filed 2024-03-01 | -$27.00M 10-K · filed 2024-03-01 |
| 2023-09-30 | -$2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$14.92M derived: sum of 2 quarters · filed 2023-11-09 | -$26.14M 10-Q · filed 2023-11-09 | $28.77M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | -$12.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$23.66M 10-Q · filed 2023-08-09 | $31.26M derived: sum of 3 quarters · filed 2024-03-01 | $14.33M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | -$11.22M 10-Q · filed 2023-05-10 | $43.69M derived: sum of 2 quarters · filed 2024-03-01 | $26.76M derived: sum of 3 quarters · filed 2024-03-01 | $13.04M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $54.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $37.98M derived: sum of 2 quarters · filed 2024-03-01 | $24.26M derived: sum of 3 quarters · filed 2024-03-01 | -$2.42M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$16.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$30.65M derived: sum of 2 quarters · filed 2023-11-09 | -$57.34M 10-Q · filed 2023-11-09 | -$102.59M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$40.41M 10-Q · filed 2023-08-09 | -$85.66M derived: sum of 3 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$26.68M 10-Q · filed 2023-05-10 | -$71.93M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | -$45.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$235.78M 10-K · filed 2023-03-01 | ||
| 2021-09-30 | -$190.53M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | -$262.75M 10-K · filed 2023-03-01 | |||
| 2017-03-31 | -$50.03M 10-Q · filed 2017-05-10 | -$78.14M derived: sum of 2 quarters · filed 2017-05-10 | -$90.57M derived: sum of 3 quarters · filed 2017-05-10 | -$122.71M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | -$28.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$40.55M derived: sum of 2 quarters · filed 2017-03-01 | -$72.68M derived: sum of 3 quarters · filed 2017-03-01 | -$98.99M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$12.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$44.57M derived: sum of 2 quarters · filed 2016-11-09 | -$70.88M 10-Q · filed 2016-11-09 | -$104.62M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-06-30 | -$32.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$58.44M 10-Q · filed 2016-08-09 | -$92.19M derived: sum of 3 quarters · filed 2017-05-10 | -$124.17M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-03-31 | -$26.31M 10-Q · filed 2017-05-10 | -$60.05M derived: sum of 2 quarters · filed 2017-05-10 | -$92.04M derived: sum of 3 quarters · filed 2017-05-10 | -$138.65M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$33.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$65.73M derived: sum of 2 quarters · filed 2017-03-01 | -$112.34M derived: sum of 3 quarters · filed 2017-03-01 | -$168.86M 10-K · filed 2017-03-01 |
| 2015-09-30 | -$31.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$78.60M derived: sum of 2 quarters · filed 2016-11-09 | -$135.11M 10-Q · filed 2016-11-09 | -$177.65M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$46.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$103.13M 10-Q · filed 2016-08-09 | -$145.67M derived: sum of 3 quarters · filed 2017-03-01 | -$182.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$56.51M 10-Q · filed 2016-05-10 | -$99.05M derived: sum of 2 quarters · filed 2017-03-01 | -$135.43M derived: sum of 3 quarters · filed 2017-03-01 | -$186.87M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$42.54M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$78.92M derived: sum of 2 quarters · filed 2017-03-01 | -$130.36M derived: sum of 3 quarters · filed 2017-03-01 | -$175.16M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$36.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$87.82M derived: sum of 2 quarters · filed 2015-11-12 | -$132.62M 10-Q · filed 2015-11-12 | -$167.80M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | -$51.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$96.24M 10-Q · filed 2015-08-13 | -$131.43M derived: sum of 3 quarters · filed 2016-03-11 | -$164.36M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | -$44.80M 10-Q · filed 2015-05-13 | -$79.99M derived: sum of 2 quarters · filed 2016-03-11 | -$112.92M derived: sum of 3 quarters · filed 2016-03-11 | -$137.27M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$35.19M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$68.12M derived: sum of 2 quarters · filed 2016-03-11 | -$92.47M derived: sum of 3 quarters · filed 2016-03-11 | -$120.96M 10-K · filed 2016-03-11 |
| 2013-09-30 | -$32.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$57.28M derived: sum of 2 quarters · filed 2014-11-12 | -$85.77M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | -$24.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$52.84M 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | -$28.49M 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | -$119.11M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |